Please provide your email address to receive an email when new articles are posted on . “While the results with PCV7 are in line with prelicensure efficacy study, no efficacy data are available for ...

(HealthDay News) – A model shows that replacing the current 23-valent pneumococcal polysaccharide vaccine (PPSV23) with the 13-valent pneumococcal conjugate vaccine (PCV13) might prevent more ...

Please provide your email address to receive an email when new articles are posted on . Research has shown that bacteremic pneumococcal pneumonia may peak in late winter. According to the CDC, the ...

study confirms shingles vaccine effective in elderly with ESRD ACIP changed the recommended interval between PCV13 followed by PPSV23 (PCV13-PPSV23 sequence) from 6-12 months to ≥1 year for ...

Give the 13-valent pneumococcal conjugate vaccine to senior patients Give the 13-valent pneumococcal conjugate vaccine along with the 23-valent pneumococcal polysaccharide vaccine to all patients aged ...

The pneumococcal vaccine PCV13 has been found to be effective in the prevention of invasive pneumococcal disease in African children without HIV. The pneumococcal vaccine PCV13 has replaced the PCV7 ...

Shingles For most serotypes, there is no significant difference in the protection conferred from four different pneumococcal vaccine schedules. HealthDay News — The immunogenicity of 13-valent ...

Background. Pediatrie respiratory infections caused by antibiotic-nonsusceptible Streptococcus pneumoniae (ANSP) continue to present an important challenge, even after introduction of 7-valent ...

VIENNA — Pneumococcal vaccination administered 1 month prior to starting methotrexate (MTX) in patients with rheumatoid arthritis (RA) allows a significantly higher immunological response at 1 month ...

Children between the ages of 6 and 18 years with immune deficiency disorders and other high-risk conditions should receive a single dose of PCV13, according to a new recommendation from the American ...